Cost of Illness (COI) Analysis of Sickle Cell Disease (SCD) in Greece


Voskaridou E1, Vlachaki E2, Delicou S3, Markouri A4, Stafylas P5, Avgitidou A5, Papastefanou V6, Pantelidou D7, Kourakli A8, Kattamis A9
1Laiko General Hospital, Athens, Greece, 2Hippokration General Hospital, Thessaloniki, Greece, 3Hippokration General Hospital, Athens, Greece, 4Novartis Hellas, athens, A1, Greece, 5HealThink, Thessaloniki, Greece, 6Novartis Hellas, Thessaloniki, 54, Greece, 7AHEPA University General Hospital, Thessaloniki, Greece, 8University of Patras Medical School, Patras, Greece, 9First Department of Pediatrics, National and Kapodistrian University of Athens, 'Aghia Sophia' Children's Hospital, Athens, Greece


SCD is associated with a substantial economic burden, since routine and lifelong care is needed to treat disease and its serious complications. The population of SCD patients is growing due to early diagnosis and improved quality of care resulting in patients’ increased survival. The aim of this analysis is to provide the first estimate on the direct costs associated with SCD in Greece.


The methodology used in our study follows the standards of the micro-costing approach. A retrospective COI study was conducted from the Greek National Organization for Health Care Provision (ΕΟPYY) perspective for a 12-month period. SCD prevalence derives from the National Registry for Haemoglobinopathies in Greece (1.032 patients). Resource use components were collected from six leading haematologists using the modified Delphi method. The COI model approximates the real-life annual cost of SCD as the sum of drug acquisition, resource use and hospitalization costs.


The annual direct medical cost attributable to SCD management in Greece was estimated at €9,045,299. The key cost driver is the drug acquisition cost (68% of the total cost). Hospitalization cost is the second component (22%) followed by resource use costs (10%). A small proportion of patients account for most of the cost. Total costs of managing SCD are estimated at €8,765/patient/year.


The present analysis shows that SCD comprises a significant economic burden, mainly driven by drug acquisition costs. Our findings are consistent with other studies estimating SCD costs. Despite some limitations, the present study constitutes the first comprehensive COI analysis of SCD in Greece. However, there are certain aspects of SCD-related costs that have not been captured in this study, such as direct non-medical and indirect costs and long-term management costs of serious chronic complications, which might increase even more the total cost of managing SCD.

Conference/Value in Health Info

2021-11, ISPOR Europe 2021, Copenhagen, Denmark

Value in Health, Volume 24, Issue 12, S2 (December 2021)




Economic Evaluation


Rare and Orphan Diseases

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now